Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma.

Compton LA, Hiebert SW
Cancer Cell. 2010 17 (4): 315-6

PMID: 20385356 · DOI:10.1016/j.ccr.2010.03.012

Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.

Copyright 2010 Elsevier Inc. All rights reserved.

MeSH Terms (6)

DNA-Binding Proteins Humans Lymphoma, B-Cell Nuclear Receptor Co-Repressor 2 Precision Medicine Proto-Oncogene Proteins c-bcl-6

Connections (2)

This publication is referenced by other Labnodes entities: